1039 related articles for article (PubMed ID: 26965997)
41. Integrated analysis of expression profiling data identifies three genes in correlation with poor prognosis of triple-negative breast cancer.
Zhang C; Han Y; Huang H; Min L; Qu L; Shou C
Int J Oncol; 2014 Jun; 44(6):2025-33. PubMed ID: 24676531
[TBL] [Abstract][Full Text] [Related]
42. [Identification of disease targets for precision medicine by integrative analysis of multi-omics data].
Xie BB; Yang YD; Ding N; Fang XD
Yi Chuan; 2015 Jul; 37(7):655-63. PubMed ID: 26351165
[TBL] [Abstract][Full Text] [Related]
43. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
44. Comparative analysis of protein interactome networks prioritizes candidate genes with cancer signatures.
Li Y; Sahni N; Yi S
Oncotarget; 2016 Nov; 7(48):78841-78849. PubMed ID: 27791983
[TBL] [Abstract][Full Text] [Related]
45. Genome-wide profiling of AP-1-regulated transcription provides insights into the invasiveness of triple-negative breast cancer.
Zhao C; Qiao Y; Jonsson P; Wang J; Xu L; Rouhi P; Sinha I; Cao Y; Williams C; Dahlman-Wright K
Cancer Res; 2014 Jul; 74(14):3983-94. PubMed ID: 24830720
[TBL] [Abstract][Full Text] [Related]
46. The omics of triple-negative breast cancers.
Xu H; Eirew P; Mullaly SC; Aparicio S
Clin Chem; 2014 Jan; 60(1):122-33. PubMed ID: 24298072
[TBL] [Abstract][Full Text] [Related]
47. Introduction: Cancer Gene Networks.
Clarke R
Methods Mol Biol; 2017; 1513():1-9. PubMed ID: 27807826
[TBL] [Abstract][Full Text] [Related]
48. Triple-Negative Breast Cancer: Next-Generation Sequencing for Target Identification.
Marotti JD; de Abreu FB; Wells WA; Tsongalis GJ
Am J Pathol; 2017 Oct; 187(10):2133-2138. PubMed ID: 28734944
[TBL] [Abstract][Full Text] [Related]
49. MOBCdb: a comprehensive database integrating multi-omics data on breast cancer for precision medicine.
Xie B; Yuan Z; Yang Y; Sun Z; Zhou S; Fang X
Breast Cancer Res Treat; 2018 Jun; 169(3):625-632. PubMed ID: 29429018
[TBL] [Abstract][Full Text] [Related]
50. Genetic Markers in Triple-Negative Breast Cancer.
Sporikova Z; Koudelakova V; Trojanec R; Hajduch M
Clin Breast Cancer; 2018 Oct; 18(5):e841-e850. PubMed ID: 30146351
[TBL] [Abstract][Full Text] [Related]
51. Multiomics analysis reveals CT83 is the most specific gene for triple negative breast cancer and its hypomethylation is oncogenic in breast cancer.
Chen C; Gao D; Huo J; Qu R; Guo Y; Hu X; Luo L
Sci Rep; 2021 Jun; 11(1):12172. PubMed ID: 34108519
[TBL] [Abstract][Full Text] [Related]
52. Systems Medicine Design for Triple-Negative Breast Cancer and Non-Triple-Negative Breast Cancer Based on Systems Identification and Carcinogenic Mechanisms.
Yeh SJ; Hsu BJ; Chen BS
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802957
[TBL] [Abstract][Full Text] [Related]
53. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
54. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
55. Genome profiles of pathologist-defined cell clusters by multiregional LCM and G&T-seq in one triple-negative breast cancer patient.
Zhu Z; Wang W; Lin F; Jordan T; Li G; Silverman S; Qiu S; Joy AA; Chen C; Hockley DL; Zhang X; Zhou Q; Postovit LM; Zhang X; Hou Y; Mackey JR; Li B; Wong GK
Cell Rep Med; 2021 Oct; 2(10):100404. PubMed ID: 34755126
[TBL] [Abstract][Full Text] [Related]
56. Pilot Study on MAGE-C2 as a Potential Biomarker for Triple-Negative Breast Cancer.
Zhao Q; Xu WT; Shalieer T
Dis Markers; 2016; 2016():2325987. PubMed ID: 27843173
[No Abstract] [Full Text] [Related]
57. MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer.
Mathe A; Scott RJ; Avery-Kiejda KA
Int J Mol Sci; 2015 Nov; 16(12):28347-76. PubMed ID: 26633365
[TBL] [Abstract][Full Text] [Related]
58. Reconstruction of pathway modification induced by nicotinamide using multi-omic network analyses in triple negative breast cancer.
Kim JY; Lee H; Woo J; Yue W; Kim K; Choi S; Jang JJ; Kim Y; Park IA; Han D; Ryu HS
Sci Rep; 2017 Jun; 7(1):3466. PubMed ID: 28615672
[TBL] [Abstract][Full Text] [Related]
59. Development of triple-negative breast cancer radiosensitive gene signature and validation based on transcriptome analysis.
Wushou A; Jiang YZ; Hou J; Liu YR; Guo XM; Shao ZM
Breast Cancer Res Treat; 2015 Nov; 154(1):57-62. PubMed ID: 26476726
[TBL] [Abstract][Full Text] [Related]
60. KLF4 and NANOG are prognostic biomarkers for triple-negative breast cancer.
Nagata T; Shimada Y; Sekine S; Moriyama M; Hashimoto I; Matsui K; Okumura T; Hori T; Imura J; Tsukada K
Breast Cancer; 2017 Mar; 24(2):326-335. PubMed ID: 27300169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
